MedElevator
Войти в исследования HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Castellsagué Xavier, Alemany Laia, Quer Miquel, Halec Gordana, Quirós Beatriz, Tous Sara, Clavero Omar, Alòs Llúcia, Biegner Thorsten, Szafarowski Tomasz, Alejo Maria, Holzinger Dana, Cadena Enrique, Claros Edith, Hall Gillian, Laco Jan, Poljak Mario, Benevolo Maria, Kasamatsu Elena, Mehanna Hisham, Ndiaye Cathy, Guimerà Núria, Lloveras Belen, León Xavier, Ruiz-Cabezas Juan C, Alvarado-Cabrero Isabel, Kang Chang-Suk, Oh Jin-Kyoung, Garcia-Rojo Marcial, Iljazovic Ermina, Ajayi Oluseyi F, Duarte Flora, Nessa Ashrafun, Tinoco Leopoldo, Duran-Padilla Marco A, Pirog Edyta C, Viarheichyk Halina, Morales Hesler, Costes Valérie, Félix Ana, Germar Maria Julieta V, Mena Marisa, Ruacan Arzu, Jain Asha, Mehrotra Ravi, Goodman Marc T, Lombardi Luis Estuardo, Ferrera Annabelle, Malami Sani, Albanesi Estela I, Dabed Pablo, Molina Carla, López-Revilla Rubén, Mandys Václav, González Manuel E, Velasco Julio, Bravo Ignacio G, Quint Wim, Pawlita Michael, Muñoz Nubia, de Sanjosé Silvia, Xavier Bosch F, ICO International HPV in Head and Neck Cancer Study Group
Аннотация
METHODS: Formalin-fixed, paraffin-embedded cancer tissues of the oral cavity (OC), pharynx, and larynx were collected from pathology archives in 29 countries. All samples were subject to histopathological evaluation, DNA quality control, and HPV-DNA detection. Samples containing HPV-DNA were further subject to HPV E6*I mRNA detection and to p16(INK4a), pRb, p53, and Cyclin D1 immunohistochemistry. Final estimates of HPV-AFs were based on HPV-DNA, HPV E6*I mRNA, and/or p16(INK4a) results.
RESULTS: A total of 3680 samples yielded valid results: 1374 pharyngeal, 1264 OC, and 1042 laryngeal cancers. HPV-AF estimates based on positivity for HPV-DNA, and for either HPV E6*I mRNA or p16(INK4a), were 22.4%, 4.4%, and 3.5% for cancers of the oropharynx, OC, and larynx, respectively, and 18.5%, 3.0%, and 1.5% when requiring simultaneous positivity for all three markers. HPV16 was largely the most common type. Estimates of HPV-AF in the oropharynx were highest in South America, Central and Eastern Europe, and Northern Europe, and lowest in Southern Europe. Women showed higher HPV-AFs than men for cancers of the oropharynx in Europe and for the larynx in Central-South America.
CONCLUSIONS: HPV contribution to HNCs is substantial but highly heterogeneous by cancer site, region, and sex. This study, the largest exploring HPV attribution in HNCs, confirms the important role of HPVs in oropharyngeal cancer and drastically downplays the previously reported involvement of HPVs in the other HNCs.